HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Measuring Consumer Exposure Confounds US FDA’s Evaluation Of Cannabinoid Safety In Supplements

Executive Summary

Acting commissioner Woodcock reminds manufacturers and marketers that a consumer’s exposure to cannabidiol and other cannabinoids likely comes from using multiple products daily. “How do you control exposure of people in a nonprescription setting?”

You may also be interested in...



Hemp Supplement Sales Continue In US Without FDA Acknowledgement As Lawful Products

Decision, explained by Principal Deputy Commissioner Woodcock, turns page on FDA’s 2019 announcement, after hemp was de-scheduled in 2018 farm bill, it would consider rulemaking for lawful use of hemp in supplements.

To Reach Sweet Spot In CBD Topical Permeation, Sweet Earth Relies On Nanotechnology

Sweet Earth conducts research with NAVCO Pharmaceuticals to confirm previous finding that beneficial effect of CBD is significantly impacted by skin permeation facilitated by nanotechnology. Canadian firm's CBD topicals are formulated with 70 nanometer particles.

Congressional Report Highlights Lack of Mandatory Supplement Listing As DSHEA 2.0 Talks Continue

The Congressional Research Service published a dietary supplements report on 20 September that provides an overview of the industry and current regulatory issues, including ‘limitations’ in the US FDA’s authority over supplements and, in particular, the absence of mandatory product listing.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel